Acrivon Therapeutics (Acrivon Therapeutics) Median PS Value : $0.00 (As of Jun. 07, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Acrivon Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Acrivon Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0. Acrivon Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-06-07), Acrivon Therapeutics's share price is $7.25. Acrivon Therapeutics's Median PS Value is $0.00. Therefore, Acrivon Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Acrivon Therapeutics's Median PS Value or its related term are showing as below:

ACRV's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Acrivon Therapeutics Median PS Value Historical Data

The historical data trend for Acrivon Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrivon Therapeutics Median PS Value Chart

Acrivon Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Median PS Value

Acrivon Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Median PS Value	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Acrivon Therapeutics's Median PS Value

For the Biotechnology subindustry, Acrivon Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrivon Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Acrivon Therapeutics's Price-to-Median-PS-Value falls into.

Acrivon Therapeutics Median PS Value Calculation

Acrivon Therapeutics's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0	*
	=	0.00

10-Year Median PS Ratio is .
Acrivon Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

Acrivon Therapeutics (NAS:ACRV) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Acrivon Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	7.25	/	0.00
	=

Acrivon Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Acrivon Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Acrivon Therapeutics (Acrivon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrivon Therapeutics Inc (NAS:ACRV) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472

Website

https://www.acrivon.com

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Executives

Mary Miller	officer: Chief Legal Officer	C/O BUTTERFLY NETWORK, INC., 530 OLD WHITFIELD STREET, GUILFORD CT 06437
Peter Blume-jensen	director, officer: President and CEO	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Chione Ltd	10 percent owner	SIMOU MENARDOU 8, RIA COURT 8, OFFICE 101, 6015, LARNACA G4 CY
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Rasmus Holm-jorgensen	officer: Chief Financial Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Eric Devroe	officer: Chief Operating Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Anastasis Nikolaou	10 percent owner	C/O CHIONE LTD/ SIMOU MENARDOU 5, KIFISIA COURT,OFFICE 225, LARNACA G4 6015
Michael John Tomsicek	director	28 OVERLOOK DRIVE, BEDFORD MA 01730
Erick Gamelin	officer: Chief Medical Officer	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Kristina Masson	director, officer: EVP - Business Operations	C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN MA 02472
Ra Capital Nexus Fund Ii, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116